Reconsidering how we treat severe congenital neutropenia

Blood

Volumn 107, Issue 12, 2006, Pages 4575-4576

  Shannon, Kevin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME DELETION; CONGENITAL DISORDER; DISEASE SEVERITY; DNA DAMAGE; DOSE RESPONSE; FANCONI ANEMIA; GENE MUTATION; GRANULOCYTE; HUMAN; INCIDENCE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NOTE; PRELEUKEMIA; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME;

EID: 33745084321     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-012146     Document Type: Note

References (3)

1. Banerjee A, Shannon KM. Leukemic transformation in patients with severe congenital neutropenia. J Pediatr Hematol Oncol. 2001;23:487-495.
2. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev. 2005;19:2925-2940.
3. Dale D, Bonilla MA, Davis M, et al. A randomized controlled phase II trial of recombinant human granulocyte colony stimulating factor for treatment of severe chronic neutropenia. Blood. 1993;81:2496-2502.